Thanks Andy. Ascribe was purely a CHRISTMAS BAROOM conversation about buying a decent amount of shares for a smaller budget,Ascribe was bought in to the conversation by a friend who works in the city, he mentioned this company and said they where trying to break into not only China but also the USA? Things always look better after a few drinks and i dont wish to mislead any one,HOWEVER as a complete newly retired, novice i take on board your commments about homework and will in future try harder. WOODY56 .

woody56,

Ok thanks for your reply.

I have just trawlwd around google, and com up with a couple of snippets you may find interesting.



Managing Medicines with ascribe

Friday 17th December 2004 - Ascribe plc makes a healthy debut on AIM

Ascribe, the health IT group focusing on medicines management, today announces the commencement of dealings of its Ordinary Shares on the AIM market (AIM) of the London Stock Exchange. Seymour Pierce is acting as Nominated Adviser and as Broker to the Company. The stock market EPIC will be ASP.L.

The proceeds of the Placing of the New Ordinary Shares, expected to amount to 5 million (before expenses) will be used by the Company, amongst other things, to fund the acquisition of Protechnic Exeter Limited.

Stephen Critchlow, Chairman and Chief Executive of Ascribe, said: We are delighted that the flotation of the Company has been completed successfully. The listing will enable us to take Ascribe to the next stage of its development and maximise any acquisition opportunities for the Company within the international healthcare market. Our strategy is to build on our position in the medicines management market through organic growth and through a number of acquisitions of profitable companies, such as Protechnic Exeter, which offer complementary established systems to customers needing a medicines management solution.


Source : http://www.ascribe.com/?Page=02+News+%26+Events%2F01+ascribe+News.txt

A copy of the AIM listing prospectus can be viewed here;


http://www.ascribe.com/UserContent/03%20Investor%20Relations/Ascribe%20plc%20Prospectus%202004.pdf


I think you will find all the required information in here.

A new article is available HERE